A Phase 1 Open-Label, Multicenter, Single and Multiple Ascending Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Lurasidone in Subjects 6 to 17 Years Old With Schizophrenia Spectrum, Bipolar Spectrum, Autistic Spectrum Disorder, or Other Psychiatric Disorders

Trial Profile

A Phase 1 Open-Label, Multicenter, Single and Multiple Ascending Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Lurasidone in Subjects 6 to 17 Years Old With Schizophrenia Spectrum, Bipolar Spectrum, Autistic Spectrum Disorder, or Other Psychiatric Disorders

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs Lurasidone (Primary)
  • Indications Autistic disorder; Bipolar disorders; Psychotic disorders
  • Focus Pharmacokinetics
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 26 Nov 2015 Results published in the Clinical Therapeutics
    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Dec 2012 Planned number of patients changed from 60 to 100 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top